HomeACADEMIA
ACADEMIA

Atherosclerosis Society Issues Statement on Use of PCSK9 Inhibitors, Recommending for Patients with FH, Secondary Prevention in High-Risk Patients
(Mar.6.2018)

Atsushi Nohara
The Japan Atherosclerosis Society (JAS) issued a statement on the proper use of PCSK9 inhibitors on March 2. These drugs are covered by health insurance for the primary prevention of coronary artery diseases (CAD) other than familial hypercholesterolemia (FH), but the statement says they should mainly be used in FH patients and for secondary prevention in high-risk patients ...
(LOG IN FOR FULL STORY)